Arcus Biosciences Inc
NYSE:RCUS

Watchlist Manager
Arcus Biosciences Inc Logo
Arcus Biosciences Inc
NYSE:RCUS
Watchlist
Price: 8.62 USD 1.29% Market Closed
Market Cap: 912.8m USD

Operating Margin
Arcus Biosciences Inc

-309.2%
Current
-156%
Average
-5%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-309.2%
=
Operating Profit
-436m
/
Revenue
141m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Arcus Biosciences Inc
NYSE:RCUS
913.7m USD
-309%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
327.3B USD
30%
US
Amgen Inc
NASDAQ:AMGN
155.6B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
135.1B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.3B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
116.3B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
55.2B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.4B USD
-5%

Arcus Biosciences Inc
Glance View

Market Cap
913.7m USD
Industry
Biotechnology

Arcus Biosciences Inc., founded in 2015 and based in California, emerges not just as a company, but as a dynamic player in the biopharmaceutical arena with a fervent focus on innovative cancer therapies. The company's narrative is centered around harnessing the power of immunotherapy to combat cancer, a testament to its commitment to push the frontiers of medicine. At the core of Arcus's strategy is its proprietary pipeline of novel molecules designed to promote antitumor immune responses, particularly small-molecule drugs and antibodies. By marrying cutting-edge science with practical clinical applications, Arcus aims to provide treatments that enhance the body's immune response against cancer, offering hope to patients and healthcare providers alike. As Arcus Biosciences spins its operational wheel, its financial engine is fueled primarily through strategic partnerships and licensing agreements. The company collaborates with major pharmaceutical players to co-develop and commercialize its promising candidates, allowing it to share the risks and rewards inherent in drug development. These partnerships not only provide upfront payments and milestone-based financial inflows but also broaden the scope of clinical trials and expedite the pathway to market availability. By aligning their interests with larger entities invested in cutting-edge oncology solutions, Arcus is positioned to capitalize on the symbiotic relationship between innovative early-stage science and the expansive reach of established pharmaceutical channels, striving to bring transformative therapies to the global market.

RCUS Intrinsic Value
11.27 USD
Undervaluation 23%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-309.2%
=
Operating Profit
-436m
/
Revenue
141m
What is the Operating Margin of Arcus Biosciences Inc?

Based on Arcus Biosciences Inc's most recent financial statements, the company has Operating Margin of -309.2%.

Back to Top